Gossamer Bio, Inc. financial data

Symbol
GOSS on Nasdaq
Industry
Pharmaceutical Preparations
Location
3013 Science Park, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 728 % +38.9%
Debt-to-equity 369 %
Return On Equity -117 % -103%
Return On Assets -25 % +69.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 226M shares +0.4%
Common Stock, Shares, Outstanding 226M shares +137%
Entity Public Float 98M USD -81.9%
Common Stock, Value, Issued 23K USD +130%
Weighted Average Number of Shares Outstanding, Basic 226M shares +137%
Weighted Average Number of Shares Outstanding, Diluted 239M shares +150%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 95.8M USD
General and Administrative Expense 36.6M USD -17.7%
Operating Income (Loss) -79.4M USD +61.2%
Nonoperating Income (Expense) 2.97M USD -58.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 53.7M USD
Income Tax Expense (Benefit) 4.44M USD
Net Income (Loss) Attributable to Parent -80.9M USD +60.9%
Earnings Per Share, Basic -0.18 USD/shares +91.7%
Earnings Per Share, Diluted -0.18 USD/shares +91.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 86.9M USD +135%
Marketable Securities, Current 268M USD +114%
Accounts Receivable, after Allowance for Credit Loss, Current 3.63M USD
Assets, Current 371M USD +114%
Property, Plant and Equipment, Net 824K USD -73%
Operating Lease, Right-of-Use Asset 1.66M USD -63.4%
Other Assets, Noncurrent 59K USD -92.3%
Assets 373M USD +105%
Accounts Payable, Current 1M USD -54.6%
Employee-related Liabilities, Current 7.82M USD -4.65%
Accrued Liabilities, Current 16.3M USD +14.4%
Contract with Customer, Liability, Current 17M USD
Liabilities, Current 45.2M USD +12.6%
Contract with Customer, Liability, Noncurrent 49.7M USD
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 292M USD +19.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -518K USD -7.69%
Retained Earnings (Accumulated Deficit) -1.2B USD -7.19%
Stockholders' Equity Attributable to Parent 81.5M USD
Liabilities and Equity 373M USD +105%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -52.3M USD +1.3%
Net Cash Provided by (Used in) Financing Activities -2.56M USD -0.75%
Net Cash Provided by (Used in) Investing Activities 61.7M USD +607%
Common Stock, Shares Authorized 700M shares 0%
Common Stock, Shares, Issued 226M shares +137%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.75M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 86.9M USD +135%
Interest Paid, Excluding Capitalized Interest, Operating Activities 367K USD -44.6%
Deferred Tax Assets, Valuation Allowance 221M USD +8.5%
Deferred Tax Assets, Gross 222M USD +7.92%
Operating Lease, Liability 1.83M USD -63.2%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -80.9M USD +60.9%
Lessee, Operating Lease, Liability, to be Paid 1.86M USD -64.5%
Property, Plant and Equipment, Gross 6.5M USD -35.6%
Operating Lease, Liability, Current 1.83M USD -41.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 144K USD -95.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 144K USD -95.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 30K USD -88.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 144K USD -91.7%
Deferred Tax Assets, Operating Loss Carryforwards 123M USD -4.65%
Unrecognized Tax Benefits 13.7M USD +29.2%
Operating Lease, Payments 3.4M USD -2.86%
Depreciation, Depletion and Amortization 1.2M USD -34.9%
Share-based Payment Arrangement, Expense 29.1M USD -8.3%
Interest Expense 13.1M USD -5.56%